Retinal Pigment Epithelium Transplantation in Retinal Disease: Clinical Trial Development, Challenges, and Future Directions
Biomolecules · 15.08.2025 · 15 (8) · 1167
DOI: 10.3390/biom15081167 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 15.08.2025. Verfasst von Qin Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Retinal Pigment Epithelium, Macular Degeneration, Retinal Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the Claffy Foundation Bright Idea Grant, Natural Science Foundation of Sichuan Province.
Abstract (Originalsprache)
Replacement of the retinal pigment epithelium (RPE) is emerging as a promising approach to treat degenerative retinal diseases, including age-related macular degeneration and Stargardt disease, in which RPE function cannot otherwise be restored. Despite the limitations of existing treatments, advances in cell sourcing and surgical methods have enabled initial human trials of RPE transplantation, with early results indicating potential efficacy. This review comprehensively examines the evolution of RPE transplantation in recent decades, highlighting the advantages and limitations of different cell sources and delivery methods. Current clinical trial data are analyzed with a particular focus on immune rejection risks, surgical complications, and long-term safety. Despite encouraging safety profiles, achieving consistent and sustained visual improvement remains a challenge, as vision outcomes might be influenced by factors such as disease stage at intervention, transplantation site, number of cells transplanted, and duration of follow-up. Key challenges, such as cell or graft survival and integration with the host retina, are discussed in depth, as overcoming these obstacles is essential for achieving stable and effective RPE replacement. Future research directions, including innovations in biomaterials, molecular modification strategies, and personalized approaches, hold promise for enhancing the efficacy and durability of RPE transplantation for retinal disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, China.
- Save Sight Institute, University of Sydney, Sydney, NSW 2015, Australia.
- Intelligent Polymer Research Institute, University of Wollongong, Wollongong, NSW 2522, Australia.
- New South Wales Tissue Bank, Sydney Eye Hospital, New South Wales Organ and Tissue Donation Service, Sydney, NSW 2000, Australia.
ORCID-Profile: Qin Chen, Aine O'Connor, Mark C Gillies, Ling Zhu
Förderung
- National Natural Science Foundation of China
- the Claffy Foundation Bright Idea Grant
- Natural Science Foundation of Sichuan Province
- Claffy Foundation Bright Idea Grant
Zitieren
APA
Chen, Q., Zhang, T., Chen, Z., Zeng, J., O'Connor, A., Zhu, M., Gillies, M. C., Lu, F., & Zhu, L. (2025). Retinal Pigment Epithelium Transplantation in Retinal Disease: Clinical Trial Development, Challenges, and Future Directions. Biomolecules, 15(8), 1167. https://doi.org/10.3390/biom15081167
Vancouver
Chen Q, Zhang T, Chen Z, Zeng J, O'Connor A, Zhu M, et al. Retinal Pigment Epithelium Transplantation in Retinal Disease: Clinical Trial Development, Challenges, and Future Directions. Biomolecules. 2025;15(8):1167. doi:10.3390/biom15081167
BibTeX
@article{Chen2025,
author = {Chen, Qin and Zhang, Ting and Chen, Zhi and Zeng, Jingwen and O'Connor, Aine and Zhu, Meidong and Gillies, Mark C and Lu, Fang and Zhu, Ling},
title = {Retinal Pigment Epithelium Transplantation in Retinal Disease: Clinical Trial Development, Challenges, and Future Directions},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {8},
pages = {1167},
doi = {10.3390/biom15081167}
}
EUVIMED